drugset / Trial / NCT06632600

A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.

NCT06632600

Phase 2 Recruiting 130 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is to investigate the ability of LXE408 to clear or reduce the level of parasites in the blood of people with chronic Chagas disease. Participants must have chronic Chagas disease without severe organ dysfunction.

Timeline

Start
2025-04-28
Primary completion
2027-03-22
Completion
2030-09-21

Drugs

EvaluationDrugModalityDoseRoute
Comparator Benznidazole Small molecule Oral
Subject LXE408 Small molecule Oral

Indications